Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Ifinatamab deruxtecan |
| Synonyms | |
| Therapy Description |
Ifinatamab deruxtecan (DS-7300a) is a monoclonal antibody targeting B7-H3 (CD276) conjugated to a DNA topoisomerase I inhibitor which may lead to antitumor activities (Ann Oncol (2023) 34 (suppl_2):S481-S482). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Ifinatamab deruxtecan | DS7300a|DS 7300a|DS7300|DS 7300|DS-7300|DS-7300a|I-DXd | CD276 Antibody 26 | Ifinatamab deruxtecan (DS-7300a) is a monoclonal antibody targeting B7-H3 (CD276) conjugated to a DNA topoisomerase I inhibitor which may lead to antitumor activities (Ann Oncol (2023) 34 (suppl_2):S481-S482). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07535359 | Expanded access | Ifinatamab deruxtecan | Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer | No longer available | USA | 0 |
| NCT06863272 | Phase Ib/II | Ifinatamab deruxtecan Docetaxel Abiraterone + Ifinatamab deruxtecan Enzalutamide + Ifinatamab deruxtecan Ifinatamab deruxtecan + ODM-208 | A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | Recruiting | USA | TUR | POL | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 3 |
| NCT04145622 | Phase Ib/II | Ifinatamab deruxtecan | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Active, not recruiting | USA | 1 |
| NCT06203210 | Phase III | Ifinatamab deruxtecan Amrubicin Lurbinectedin Topotecan | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | 5 |
| NCT06780098 | Phase II | Raludotatug deruxtecan Docetaxel Ifinatamab deruxtecan | Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) | Recruiting | USA | TUR | POL | ITA | ISR | HUN | GRC | ESP | DEU | 2 |
| NCT06780137 | Phase Ib/II | HPN328 + Ifinatamab deruxtecan Durvalumab + HPN328 HPN328 Ifinatamab deruxtecan | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | Recruiting | USA | TUR | ISR | GBR | ESP | AUS | ARG | 5 |
| NCT06780085 | Phase II | Ifinatamab deruxtecan Docetaxel Raludotatug deruxtecan | A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) | Recruiting | USA | TUR | POL | ITA | ISR | HUN | GRC | ESP | DEU | 1 |
| NCT06925737 | Phase III | Docetaxel + Prednisone Ifinatamab deruxtecan | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Recruiting | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | BRA | AUT | AUS | ARG | 14 |
| NCT05280470 | Phase II | Ifinatamab deruxtecan | DS-7300a in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Active, not recruiting | USA | FRA | ESP | DEU | 4 |
| NCT07405151 | Phase Ib/II | Ifinatamab deruxtecan | A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) | Recruiting | USA | NOR | CZE | CHE | BRA | 6 |
| NCT06644781 | Phase III | Docetaxel + Irinotecan + Paclitaxel Ifinatamab deruxtecan | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | Recruiting | USA | SWE | ROU | POL | NOR | NLD | ITA | GBR | FRA | ESP | DNK | DEU | BEL | 4 |
| NCT06330064 | Phase Ib/II | Ifinatamab deruxtecan | A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) | Recruiting | USA | TUR | POL | NLD | ITA | IRL | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 5 |
| NCT07630974 | Phase Ib/II | Ifinatamab deruxtecan | A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) | Recruiting | USA | SWE | NLD | ISR | FRA | ESP | DNK | BEL | AUS | 1 |
CKB BOOST